ApatinibTablets
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Trial Timeline
May 15, 2015 → Sep 3, 2020
NCT ID
NCT02426034About ApatinibTablets
ApatinibTablets is a approved stage product being developed by Jiangsu Hengrui Medicine for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02426034. Target conditions include Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
What happened to similar drugs?
15 of 20 similar drugs in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02426034 | Approved | Completed |
Competing Products
20 competing products in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma